Action IGC IGC PHARMA, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues IGC Pharma, Inc.

Actions

IGC

US45408X3089

Temps réel estimé Cboe BZX
Autres places de cotation
 21:21:55 28/06/2024 		Varia. 5j. Varia. 1 janv.
0,415 USD -2,35% Graphique intraday de IGC Pharma, Inc. -24,05% +49,13%
25/06 Les résultats précliniques du TGR-63 d'IGC Pharma, Inc. démontrent une réduction substantielle de la plaque amyloïde, une caractéristique clé de la maladie d'Alzheimer CI
24/06 IGC Pharma, Inc. annonce ses résultats pour l'exercice terminé le 31 mars 2024 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
IGC Pharma, Inc.'S TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, A Key Hallmark of Alzheimer's Disease
IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
IGC Pharma, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol
IGC Pharma, Inc. Publishes Study in European Society of Medicine Investigating Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol
IGC Pharma Announces Patient Enrollment at Neurostudies, Inc. in Phase 2 Trial Investigating IGC-AD1
IGC Pharma Begins Patient Enrollment for Mid-Stage Trial of IGC-AD1 to Treat Alzheimer's-Related Agitation
IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1
IGC Pharma, Inc. Announces Patient Enrollment At Neurostudies in Phase 2 Trial Investigating IGC-AD1
IGC Pharma to Attend BIO International Convention 2024
6.7 Million Americans Live With Alzheimer’s – IGC Pharma Believes They Deserve Treatment Options Without Black Box Warnings
IGC PHARMA : Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
IGC-AD1'S Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two
IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two
IGC Pharma, Inc Announces Interim Data from Its Phase 2 Clinical Trial Demonstrates Clinically Significant Reduction, Approaching Statistical Significance, in Agitation in Alzheimer?S At Week Two Compared to Placebo
IGC Pharma Adds Advisor in Artificial Intelligence
IGC Pharma : Announces Positive Interim Results for IGC-AD1 in - Form 8-K
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action IGC
  4. Actualités IGC Pharma, Inc.
  5. Autres langues